Omar Boraie, the President of a New Brunswick-based real estate development firm Boraie Development LLC., and a well-known philanthropist extended his support to set up a Chair n Genomic Science at Rutgers Cancer Institute, http://patch.com/new-jersey/newbrunswick/omar-boraie-chair-genomic-science-established-rutgers-cancer-institute. The effort is to help the institute’s mission to advance in precision medicine to mainly help different cancer treatments. The institute is known for excellent education and high-class research in fostering the best talents to address the needs of modern medicine, especially in cancer treatments.
Omar has pledged $1.5 million for setting up the chair, and it is named as Omar Boraie Chair. The press release published in newswise states that the precision medicine in genomic science is focusing on how to diagnose and treat various cancers at a genetic level. It can give better outcomes, and by considering the impact of the treatment, former U.S. President Barack Obama also endorsed the treatment method in treating cancers as it gives individualized therapies. It should be noted that Rutgers Institute is the first institute in the country using genomic sequencing as a precision medicine method in patient care. Genomic sequencing is very useful in treating rare types of cancers, and the cancers with treatment options are ineffective or limited.
The progress in precision medicine would help the physicians to classify cancers into different subgenres with similar characteristics with different genetics, as this can give specific individual therapies to ensure a better outcome. “The researchers at the institute could achieve significant results in even cancers that no longer responsive. Consider if they could transmit the benefit to all the cancer patients? I hope that my contribution would help them to make significant results in precision medicine research,” said Boraie. “Mr. Omar Boraie was always in the front to make New Brunswick as a health city. His new initiative would make a tremendous impact in cancer diagnosis and treatment, it would also help millions of cancer patients across the globe,” said Robert S. DiPaola, MD, Director of Rutgers Cancer Institute.
Shridar Ganesan, MD, Ph.D., principal investigator in precision medicine trials and associate director of translational science at the institute is named as the chair. He is a medical oncologist and has more than ten years of experience at the Institute. “Since the cancer is not a single type and it is much better to classify according to the features than organ affected, the genomic analysis can open doors to better sub-classification that can help us in delivering tailored and precise therapy,” Ganesan said. “I am honored to be named as the chair, and this pledge would help to advance the research in precise medicine that can benefit all the cancer patients.”